Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Sell
18
NUWE Quote, Financials, Valuation and Earnings
Last price:
$1.12
Seasonality move
:
-14.32%
Day range:
$1.11 - $1.13
52-week range:
$0.92 - $16.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.20x
P/B ratio:
0.75x
Volume:
36.5K
Avg. volume:
140.2K
1-year change:
-92.59%
Market cap:
$4.9M
Revenue:
$8.7M
EPS (TTM):
-$38.55
Analysts' Opinion
-
Consensus RatingNuwellis has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.00, Nuwellis has an estimated upside of 1060.71% from its current price of $1.12.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.00 representing 100% downside risk from its current price of $1.12.
Fair Value
-
According to the consensus of 1 analyst, Nuwellis has 1060.71% upside to fair value with a price target of $13.00 per share.
NUWE vs. S&P 500
-
Over the past 5 trading days, Nuwellis has underperformed the S&P 500 by -3.94% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Nuwellis does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nuwellis revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Nuwellis reported revenues of $2.3M.
Earnings Growth
-
Nuwellis has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Nuwellis reported earnings per share of -$0.44.
Enterprise value:
-194.1K
EV / Invested capital:
-0.03x
Price / LTM sales:
0.20x
EV / EBIT:
--
EV / Revenue:
-0.02x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.02x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$5.7M
Return On Assets:
-142.36%
Net Income Margin (TTM):
-127.75%
Return On Equity:
-800.59%
Return On Invested Capital:
-800.59%
Operating Margin:
-102.8%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $8.5M | $8.9M | $8.7M | $2.6M | $2.3M | |
| Gross Profit | $4.8M | $5M | $5.7M | $1.4M | $1.4M | |
| Operating Income | -$17.2M | -$17.6M | -$11M | -$3.6M | -$2.4M | |
| EBITDA | -$4.9M | -$15.7M | -$5.7M | -$1.9M | -$1.4M | |
| Diluted EPS | -$4,369.40 | -$470.92 | -$38.55 | -$78.40 | -$0.44 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $18.5M | $28.1M | $22.8M | $8.2M | $8.9M | |
| Total Assets | $20M | $30.4M | $24.7M | $9.8M | $9.9M | |
| Current Liabilities | $3.6M | $3.3M | $4.7M | $3.2M | $2.6M | |
| Total Liabilities | $3.7M | $4.5M | $12.3M | $6.6M | $3.3M | |
| Total Equity | $16.3M | $25.9M | $12.4M | $3.2M | $6.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$15.1M | -$17.9M | -$9.6M | -$2.8M | -$1.5M | |
| Cash From Investing | $14.7M | $330K | -$60K | $36K | -$23K | |
| Cash From Financing | $9.4M | $3.7M | $11M | $1.6M | $4.7M | |
| Free Cash Flow | -$15.3M | -$18.2M | -$9.7M | -$2.7M | -$1.5M | |
NUWE
Sector
Market Cap
$4.9M
$39.2M
Price % of 52-Week High
6.96%
45.93%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
-92.59%
-38.63%
Beta (5-Year)
0.359
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.14
200-day SMA
Sell
Level
$2.26
Bollinger Bands (100)
Sell
Level
1.04 - 1.62
Chaikin Money Flow
Sell
Level
-466.6M
20-day SMA
Sell
Level
$1.21
Relative Strength Index (RSI14)
Sell
Level
40.48
ADX Line
Sell
Level
17.76
Williams %R
Buy
Level
-91.6667
50-day SMA
Sell
Level
$1.21
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
491.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-41.7391)
Sell
CA Score
(Annual)
Level (-2.6833)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (9.7506)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
Stock Forecast FAQ
In the current month, NUWE has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The NUWE average analyst price target in the past 3 months is $13.00.
-
Where Will Nuwellis Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nuwellis share price will rise to $13.00 per share over the next 12 months.
-
What Do Analysts Say About Nuwellis?
Analysts are divided on their view about Nuwellis share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nuwellis is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is Nuwellis's Price Target?
The price target for Nuwellis over the next 1-year time period is forecast to be $13.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is NUWE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nuwellis is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of NUWE?
You can purchase shares of Nuwellis via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nuwellis shares.
-
What Is The Nuwellis Share Price Today?
Nuwellis was last trading at $1.12 per share. This represents the most recent stock quote for Nuwellis. Yesterday, Nuwellis closed at $1.12 per share.
-
How To Buy Nuwellis Stock Online?
In order to purchase Nuwellis stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
